Ok, I am now abit confused, but also very pleased.
Reading over Alteritys last shareholder news letter released in January. I must have misread this section, but ATH434 has already been given orphan drug designation for the treatment for MSA.
Therefore, would I be correct in saying that this drug will be given the green light even if results remain the same/replicated from the 202 study in the 201 study ?.
Thoughts and/or further insight would be appreciated.
What to hopefully look forward too, page-16
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $5.491K | 1.520M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 50987030 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126437200 | 27 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |